In case of relapse of acute myelogeneous leukaemia (AML) after allogeneic blood stem cell transplantation (ABSCT), the treatment options are still very limited. In a recent issue of Leukemia, Schmid et al 1 described an ingenious protocol of adoptive immunotherapy for the treatment of recurrent AML after ABSCT: low toxicity remission induction with cytarabine (Ara-C 2 Â 10 mg/m 2 /day) was followed by a second peripheral blood stem cell (PBSC) transplantation from the same donor without conditioning and granulocyte-macrophage colony-stimulating factor (GM-CSF) for 4 weeks. In patients without signs of graftversus-host disease (GvHD), interleukin-2 (IL-2) and donor lymphocyte infusion (DLI) were given afterwards. With this protocol in adults, a remission rate of 69% and a survival rate 46 months of 56% could be achieved.
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In case of relapse of acute myelogeneous leukaemia (AML) after allogeneic blood stem cell transplantation (ABSCT), the treatment options are still very limited. In a recent issue of Leukemia, Schmid et al 1 described an ingenious protocol of adoptive immunotherapy for the treatment of recurrent AML after ABSCT: low toxicity remission induction with cytarabine (Ara-C 2 Â 10 mg/m 2 /day) was followed by a second peripheral blood stem cell (PBSC) transplantation from the same donor without conditioning and granulocyte-macrophage colony-stimulating factor (GM-CSF) for 4 weeks. In patients without signs of graftversus-host disease (GvHD), interleukin-2 (IL-2) and donor lymphocyte infusion (DLI) were given afterwards. With this protocol in adults, a remission rate of 69% and a survival rate 46 months of 56% could be achieved.
Herein, we report on two children with AML who relapsed after ABSCT. Notably, both of them had the translocation t(6;11) with transcription of MLL/AF6 fusion mRNA in their leukaemic cells.
In contrast to Schmid et al who suggest low-dose Ara-C as reinduction treatment of adult patients, we applied a strategy involving an aggressive reinduction chemotherapy followed by the adoptive immunotherapy approach.
Patient 1, an 11-year-old girl, presented an AML, FAB classification M5, with translocation t(6;11) and MLL/AF6 rearrangement. First remission was achieved on day þ 42 after administration of the two induction chemotherapy courses according to the protocol AML-BFM 98. 2 At this point in time, fluorescence in situ hybridisation (FISH) showed no more MLL splitting.
She received stem cell transplantation (bone marrow (bm)) from an HLA-identical sibling after conditioning with busulphan (BU) and cyclophosphamide (CYC). No GvHD occurred with cyclosporin A (CyA) as prophylaxis. On day þ 99, MLL splitting was again detected in 1.7% of the analysed cells and immunosuppression was stopped.
At 6 months after transplantation, the first bone marrow relapse was diagnosed. Chimerism showed 30-40% autologous cells, and MLL splitting could be observed in 23% of the analysed cells. She achieved second remission, a full donor chimerism and loss of MLL splitting after chemotherapy with daunoxome, fludarabine, cytarabine and granulocyte colonystimulating factor (G-CSF).
Immunotherapy according to the protocol of Schmid et al was performed. No conditioning regimen and no GvHD prophylaxis was carried out. After the transplantation of G-CSF-mobilized PBSC (2.36 Â 10 6 and 111.9 Â 10 6 CD3-positive cells/kg bw) from the same donor, an immunotherapy with GM-CSF, IL-2 and DLI followed. Recombinant hGM-CSF (molgrammostim, Leukomaxt) (75 mg/m 2 /day) was applied from day þ 1 until day þ 28. Owing to the lack of GvHD, immunotherapy was continued: IL-2 (Aldesleukin, Proleukin s ) (10 5 IE) was administered daily from day þ 35 to þ 49 and DLI was started on day þ 35 (1 Â 10 7 CD3-positive cells/kg bw), followed every second week (2.2 Â 10 7 and 5.0 Â 10 7 CD3-positive cells/kg bw). After the third DLI, an acute GvHD II-III1 of the skin occurred, which had to be treated with steroids (max. 1 mg/kg bw) for 8 months.
Unfortunately, the patient remained in remission for only 15 months until the second relapse occurred. Chimerism analysis showed 30-40% recipient cells and MLL splitting was seen in 93% of the cells. A third remission could be achieved with cytarabine (500 mg/m 2 /day) and cladribine (9 mg/m 2 /day) for 6 days. Another stem cell transplantation (conditioning: total body irradiation and etoposide) from a second HLA-identical sibling was carried out. The patient developed acute GvHD II1 (skin, liver) and still suffers from extended chronic GvHD (skin, gut). She is still in remission without proof of MLL splitting after 2 years. At 4 and 6 months after the transplantation, 1-5% autologous cells could be detected, but resolved without intervention. The clinical course of patient 1 is shown in Figure 1 .
Patient 2, an 8-year-old boy, was diagnosed as AML-M5 with MLL/AF6 rearrangement. He went into remission on day 33 after receiving the same chemotherapy as the other patient.
At 8 months after diagnosis, stem cell transplantation was carried out from the HLA-identical sibling (conditioning: BU and CYC). Minimal residual disease (MRD) was monitored using a polymerase chain reaction (PCR) for MLL/AF6 fusion. After ABSCT, the MRD marker became negative. However, despite reduction of CyA starting on day 50, MLL/AF6 was again detected on day þ 72 and in increasing amounts during the following months. Chimerism analysis showed 1-5% of autologous cells. Repeated DLI were carried out eight times At 9 months after transplantation ( ¼ 3 weeks after the last DLI), a relapse was observed. As in the first patient a second remission, a full donor chimerism and the disappearance of MLL/AF6 could be achieved with chemotherapy including daunoxome, fludarabine, cytarabine and G-CSF. Unfortunately, the patient developed invasive aspergillosis, and hence further aggressive chemotherapy or myeloablative conditioning should be avoided.
The described immunotherapy was carried out 2 months after the relapse. G-CSF-mobilized PBSC (5 Â 10 6 CD34-positive cells/kg bw) were transfused without conditioning and GvHD prophylaxis and recombinant hGM-CSF (molgrammostim, Leukomaxt) was applied from day þ 1 to þ 28 (75 mg/m 2 / day). No signs of GvHD were observed and immunotherapy was going on. IL-2 (Aldesleukin, Proleukin s ; 10 5 IE) was administered from day þ 35 until day þ 49 and DLI were given on day þ 35 with 1 Â 10 7 , on day þ 63 with 5 Â 10 7 and on day þ 100 with 3 Â 10 8 CD3-positive cells/kg bw. The clinical course was complicated by a restrictive lung disease which had to be treated by high-dose steroid pulses for 6 months. During this time, he also developed a candidaoesophagitis with oesophageal stenoses. At 2.5 years post-PBSC and immunotherapy, the patient is without any sign of relapse, has a full donor chimerism and negative tests for MLL/AF6.
For details of the clinical course of patient 2 see Figure 2 .
In AML relapse, DLI with or without chemotherapy have a remission rate of up to 41%, but the median survival time was only 248 days. 3 An allogeneic effect was postulated because lower relapse rates were observed in case of GvHD and higher relapse rates in syngeneic transplants. In children with AML relapse, retransplantation produced a good survival rate over 10 years: 48%, with a GvHD rate of 75%. 4 Especially in our patient 2 who developed aspergillosis, we were afraid to transplant him with a standard myeloablative conditioning regimen because of a high risk of transplant-related mortality. On the other hand, he did not respond to DLI, which were carried out after proof of increased MRD before the relapse. Therefore, the new protocol of Schmid et al, without conditioning and improved immunotherapy was probably the best therapeutic option. The good response of this patient, who is 2.5 years post-PBSC with immunotherapy still in remission, may be correlated with the improved immunostimulation with GM-CSF and IL-2. In vitro AML blasts could be differentiated in dendritic cell (DC)-like cells, which showed an increased cytotoxic T-cell response compared to untreated blasts. 5 Both GM-CSF and IL-2, which induce proliferation, maturation and migration of DC and intensify the cytotoxic effect of T and NK cells, contribute to the antileukaemic effect.
It remains open whether the different clinical courses of the two patients may be associated with the different expression pattern of NG2. This chondroitin sulphate proteoglycan is specifically expressed on the cell surface of myeloid blasts in the majority of patients with abnormalities of the MLL gene. 6 In contrast to patient 2, patient 1 belonged to the small group of patients with 11q23/MLL rearrangement, but without concomitant expression of NG2. Initially, he responded nicely to immunotherapy, but remission only persisted for 15 months. Thus, NG2 expression may contribute to the persistent antileukaemic effect fortunately seen in our second patient.
